Anna Vossenkämper

Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases

Philip A. Harris, Scott B. Berger, Jae Uk Jeong et al. · Journal of Medicinal Chemistry · 2017 · 464 citations · Full text

Drug Target, Immunology, Cell Death +22

Small Extracellular Vesicles Are Key Regulators of Non-cell Autonomous Intercellular Communication in Senescence via the Interferon Protein IFITM3

Michela Borghesan, Juan Fafián‐Labora, Olga Eleftheriadou et al. · Cell Reports · 2019 · 293 citations · Full text

Paracrine Senescence, Immunology, Extracellular Microvesicles +16

Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2

Alina Mares, Afjal H. Miah, Ian E. Smith et al. · Communications Biology · 2020 · 209 citations · Full text

Developing in vitro expanded CD45RA⁺regulatory T cells as an adoptive cell therapy for Crohn's disease

James B. Canavan, Cristiano Scottà, Anna Vossenkämper et al. · Gut · 2015 · 190 citations · Full text

Association of innate immune activation with latent Epstein-Barr virus in active MS lesions

John S. Tzartos, Gulfaraz Khan, Anna Vossenkämper et al. · Neurology · 2011 · 134 citations · Full text